At diagnosis, mutations in ASXL1, DNMT3A, and TET2 dominated in CML-CP and RUNX1, IKZF1, and BCR::ABL1 in Ph+ ALL. This evidence concerns the gene DNMT3A and chronic myelogenous leukemia, BCR-ABL1 positive.